Details for New Drug Application (NDA): 211568
✉ Email this page to a colleague
NDA 211568 describes ISOTRETINOIN, which is a drug marketed by Actavis Labs Fl, Amneal Pharms Ny, Aurobindo Pharma, Upsher Smith Labs, and Zydus Pharms, and is included in six NDAs. It is available from seven suppliers. Additional details are available on the ISOTRETINOIN profile page.
The generic ingredient in ISOTRETINOIN is isotretinoin. There are thirteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.
The generic ingredient in ISOTRETINOIN is isotretinoin. There are thirteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.
Summary for 211568
| Tradename: | ISOTRETINOIN |
| Applicant: | Zydus Pharms |
| Ingredient: | isotretinoin |
| Patents: | 0 |
Suppliers and Packaging for NDA: 211568
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ISOTRETINOIN | isotretinoin | CAPSULE;ORAL | 211568 | ANDA | Zydus Pharmaceuticals USA Inc. | 70710-1022 | 70710-1022-4 | 10 BLISTER PACK in 1 CARTON (70710-1022-4) / 10 CAPSULE in 1 BLISTER PACK |
| ISOTRETINOIN | isotretinoin | CAPSULE;ORAL | 211568 | ANDA | Zydus Pharmaceuticals USA Inc. | 70710-1022 | 70710-1022-8 | 3 BLISTER PACK in 1 CARTON (70710-1022-8) / 10 CAPSULE in 1 BLISTER PACK |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 10MG | ||||
| Approval Date: | Aug 29, 2023 | TE: | AB1 | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 20MG | ||||
| Approval Date: | Aug 29, 2023 | TE: | AB1 | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 30MG | ||||
| Approval Date: | Aug 29, 2023 | TE: | AB1 | RLD: | No | ||||
Complete Access Available with Subscription
